PAAD progression involves various serotonin receptor subtypes at distinct tumor phases, with significant HTR1A and HTR1B expression observed in aggressive PAAD characterized by high Gleason scores and metastatic prostate cancer [40]. Here, HTR1B is linked to metastatic prostate carcinoma.